CN113880900B - 黄酮苷-有机胺类dpp-4抑制剂复盐化合物及其制备方法和应用 - Google Patents

黄酮苷-有机胺类dpp-4抑制剂复盐化合物及其制备方法和应用 Download PDF

Info

Publication number
CN113880900B
CN113880900B CN202111280095.3A CN202111280095A CN113880900B CN 113880900 B CN113880900 B CN 113880900B CN 202111280095 A CN202111280095 A CN 202111280095A CN 113880900 B CN113880900 B CN 113880900B
Authority
CN
China
Prior art keywords
double salt
dpp
inhibitor
baicalin
salt compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111280095.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113880900A (zh
Inventor
王化录
王鹿荧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Lalin Intelligent Technology Co ltd
Original Assignee
Hangzhou Lalin Intelligent Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Lalin Intelligent Technology Co ltd filed Critical Hangzhou Lalin Intelligent Technology Co ltd
Publication of CN113880900A publication Critical patent/CN113880900A/zh
Application granted granted Critical
Publication of CN113880900B publication Critical patent/CN113880900B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202111280095.3A 2020-10-30 2021-10-29 黄酮苷-有机胺类dpp-4抑制剂复盐化合物及其制备方法和应用 Active CN113880900B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020111909899 2020-10-30
CN202011190989 2020-10-30

Publications (2)

Publication Number Publication Date
CN113880900A CN113880900A (zh) 2022-01-04
CN113880900B true CN113880900B (zh) 2023-07-07

Family

ID=79014744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111280095.3A Active CN113880900B (zh) 2020-10-30 2021-10-29 黄酮苷-有机胺类dpp-4抑制剂复盐化合物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN113880900B (fr)
WO (1) WO2022089589A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113880900B (zh) * 2020-10-30 2023-07-07 杭州拉林智能科技有限公司 黄酮苷-有机胺类dpp-4抑制剂复盐化合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101732417B (zh) * 2010-02-09 2011-11-09 曾建国 博落回总生物碱离子对混合物的制备方法和用途
CN102086172A (zh) * 2011-01-13 2011-06-08 廖国超 沙格列汀的药用盐及其制备方法
EP2760853A4 (fr) * 2011-09-26 2015-10-28 Hetero Research Foundation Nouveaux sels de l'alogliptine
WO2013054364A2 (fr) * 2011-10-14 2013-04-18 Laurus Labs Private Limited Nouveaux sels de sitagliptine, leur procédé de préparation et compositions pharmaceutique les contenant
CN110314233B (zh) * 2019-08-12 2021-07-23 浙江养生堂天然药物研究所有限公司 包含柠檬苦素类化合物和dpp-4抑制剂的组合产品
CN113880900B (zh) * 2020-10-30 2023-07-07 杭州拉林智能科技有限公司 黄酮苷-有机胺类dpp-4抑制剂复盐化合物及其制备方法和应用

Also Published As

Publication number Publication date
WO2022089589A1 (fr) 2022-05-05
CN113880900A (zh) 2022-01-04

Similar Documents

Publication Publication Date Title
DK2547334T3 (en) NEW CONNECTIONS AND COMPOSITIONS FOR TARGETING CANCER STAM CELLS
US20170319537A1 (en) Novel methods for targeting cancer stem cells
JP2017128605A (ja) 抗ウイルス化合物の固体形態
EP3108750B1 (fr) Nouveaux composés et compositions pour le ciblage des cellules souches cancéreuses
US9249106B2 (en) Substituted hydrazide compounds and use thereof
CN115667209A (zh) 用于治疗sars的化合物
CN113880900B (zh) 黄酮苷-有机胺类dpp-4抑制剂复盐化合物及其制备方法和应用
US20220280648A1 (en) Design and efficient synthesis of lipid-fluorescein conjugates for car-t cell therapy
CN113880899B (zh) 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用
CN113801181B (zh) 黄酮苷-有机胺类抗肿瘤剂复盐化合物及其制备方法和应用
CN106963766B (zh) 一种氮杂螺酮类药物组合物及其制备方法
CN113880898B (zh) 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用
CN113880897B (zh) 黄酮苷-有机胺类酪氨酸激酶抑制剂复盐化合物及其制备方法和应用
CN116209673A (zh) 用于治疗sars的化合物
CN114075105B (zh) 富勒烯芳基多羧酸衍生物及其在抗冠状病毒感染中的应用
EP3381922B1 (fr) Cristaux d'inhibiteurs de dpp-iv dérivés de thiadiazole et leurs utilisations
CN111138282A (zh) 绿原酸l-精氨酸盐及其用途
CN113797218A (zh) 药物组合物及其制备方法和应用
KR101770014B1 (ko) 아미노벤조산 유도체의 유기 아민염 및 그 제조 방법
CN117777089A (zh) 脂质化合物和脂质纳米颗粒组合物
CN110938001A (zh) 绿原酸乙醇胺盐及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant